Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Chlodantane

From Wikipedia, the free encyclopedia

Chlodantane
Clinical data
Other namesADK-910; Chlodantan; N-(2-Adamantyl)-N-(para-chlorobenzoyl)amine; 2-(para-Chlorobenzoylamino)adamantane
Identifiers
  • N-(2-adamantyl)-4-chlorobenzamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H20ClNO
Molar mass289.80 g·mol−1
3D model (JSmol)
  • C1C2CC3CC1CC(C2)C3NC(=O)C4=CC=C(C=C4)Cl
  • InChI=1S/C17H20ClNO/c18-15-3-1-12(2-4-15)17(20)19-16-13-6-10-5-11(8-13)9-14(16)7-10/h1-4,10-11,13-14,16H,5-9H2,(H,19,20)
  • Key:VOHIYJJUKAUCCU-UHFFFAOYSA-N

Chlodantane (developmental code name ADK-910) is a drug described as an adaptogen or actoprotector "of the estrogen activity type" that was developed in Russia and was never marketed.[1][2] It is an adamantane derivative and is closely related to bromantane (N-(2-adamantyl)-N-(para-bromophenyl)amine) and other adamantanes.[2][1] It has been said to improve physical performance.[2] However, only animal or cell culture research has been conducted and it has not been studied in humans.[2] The drug is described as having a broader spectrum of activity than bromantane.[1] It also has immunostimulant effects that are said to be more pronounced than those of bromantane.[1]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Morozov IS, Ivanova IA, Lukicheva TA (2001). "Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)". Pharmaceutical Chemistry Journal. 35 (5): 235–238. doi:10.1023/A:1011905302667.
  2. 1 2 3 4 Oliynyk S, Oh S (September 2012). "The pharmacology of actoprotectors: practical application for improvement of mental and physical performance". Biomolecules & Therapeutics. 20 (5): 446–456. doi:10.4062/biomolther.2012.20.5.446. PMC 3762282. PMID 24009833.